The Medicines Company (NASDAQ:MDCO) was the target of unusually large options trading on Monday. Investors purchased 9,081 call options on the stock. This represents an increase of approximately 3,053% compared to the average daily volume of 288 call options.
Several brokerages recently issued reports on MDCO. Zacks Investment Research upgraded The Medicines from a “sell” rating to a “hold” rating in a report on Monday, December 31st. BidaskClub upgraded The Medicines from a “sell” rating to a “hold” rating in a report on Saturday, February 2nd. Oppenheimer set a $50.00 price target on The Medicines and gave the stock a “buy” rating in a report on Friday, November 9th. Cowen set a $46.00 price objective on The Medicines and gave the company a “buy” rating in a research note on Sunday, November 11th. Finally, Wolfe Research started coverage on The Medicines in a research report on Friday, December 14th. They set an “outperform” rating for the company. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $45.29.
In related news, EVP Christopher T. Cox purchased 50,300 shares of the firm’s stock in a transaction that occurred on Friday, November 16th. The stock was acquired at an average price of $19.73 per share, for a total transaction of $992,419.00. Following the completion of the acquisition, the executive vice president now owns 60,308 shares of the company’s stock, valued at approximately $1,189,876.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alexander J. Denner purchased 819,000 shares of the firm’s stock in a transaction that occurred on Friday, December 14th. The shares were bought at an average price of $20.26 per share, with a total value of $16,592,940.00. Following the acquisition, the director now directly owns 10,429 shares of the company’s stock, valued at approximately $211,291.54. The disclosure for this purchase can be found here. Insiders have purchased 1,052,589 shares of company stock valued at $20,865,236 in the last quarter. 10.29% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can increased its position in shares of The Medicines by 31.9% during the 4th quarter. Bank of Montreal Can now owns 3,139 shares of the company’s stock valued at $59,000 after purchasing an additional 760 shares during the last quarter. First Mercantile Trust Co. increased its position in shares of The Medicines by 21.6% during the 4th quarter. First Mercantile Trust Co. now owns 3,965 shares of the company’s stock valued at $76,000 after purchasing an additional 705 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of The Medicines by 61.1% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,990 shares of the company’s stock valued at $125,000 after purchasing an additional 2,651 shares during the last quarter. CIBC Private Wealth Group LLC purchased a new stake in shares of The Medicines during the 4th quarter valued at $232,000. Finally, Riverhead Capital Management LLC increased its position in shares of The Medicines by 32.2% during the 3rd quarter. Riverhead Capital Management LLC now owns 12,306 shares of the company’s stock valued at $368,000 after purchasing an additional 3,000 shares during the last quarter.
Shares of The Medicines stock opened at $24.05 on Tuesday. The Medicines has a 1 year low of $16.69 and a 1 year high of $41.57. The firm has a market cap of $1.74 billion, a PE ratio of -2.86 and a beta of 1.18. The company has a quick ratio of 2.40, a current ratio of 2.41 and a debt-to-equity ratio of 31.23.
About The Medicines
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.